Key Highlights Pharmaceutical giant Eli Lilly is purchasing psychedelic therapy company AtaiBeckley in a transaction valued at $2.8 billion cash upfront, potentially reaching $3.8 billion wit
Eli Lilly has entered into a definitive agreement to purchase AtaiBeckley for an initial payment of $2.8 billion, with up to $1 billion more tied to achieving specific development and commercial milestones. The purchase price of $6.75 per share marks a 26% increase over AtaiBeckley’s Wednesday closing value of $5.36.
Eli Lilly $LLY agreed to acquire AtaiBeckley $ATAI for up to $3.8B.
Terms: $6.75/share cash upfront, valuing AtaiBeckley at about $2.8B, plus a CVR worth up to $2.50/share tied to BPL-003 and VLS-01 milestones.
The upfront price is a roughly 40% premium to $ATAI’s 30-day VWAP.… pic.twitter.com/ZsYaRqCYul
— Wall St Engine (@wallstengine) July 16, 2026
Shares of AtaiBeckley (ATAI) soared more than 30% during premarket activity following the announcement. Eli Lilly (LLY) stock climbed approximately 0.51% in after-hours trading.
The strategic rationale behind this acquisition centers on AtaiBeckley’s flagship experimental therapy, BPL-003. This investigational medicine is a nasal spray formulation containing DMT, currently undergoing Phase 3 clinical evaluation for patients suffering from treatment-resistant depression — a challenging condition where individuals fail to respond to conventional antidepressant medications.
The treatment protocol requires patients to self-administer the spray within a clinical setting while under medical supervision for approximately two hours. Initial data from the Phase 3 program isn’t anticipated until 2029.
Beyond BPL-003, AtaiBeckley maintains a pipeline of additional psychedelic-inspired therapies, including an MDMA-related compound and a candidate targeting social anxiety disorder.
This transaction represents Lilly’s inaugural venture into the psychedelic therapeutics sector. The move comes amid growing pharmaceutical industry enthusiasm for this emerging treatment category.
AbbVie committed as much as $1.2 billion in 2024 to acquire an experimental psychedelic depression therapy from Gilgamesh Pharmaceuticals. Lilly’s entrance into the space underscores intensifying competition among major drugmakers.
The current Trump administration has provided additional momentum to the psychedelic medicine sector, issuing directives in April instructing healthcare regulatory agencies to expedite approval pathways for select psychedelic therapies while increasing government research allocations.
BMO analyst Evan Seigerman noted that AtaiBeckley “would provide differentiated exposure in psychiatry and reinforce the company’s broader effort to diversify beyond its cornerstone cardiometabolic franchise.”
The AtaiBeckley transaction fits within a broader pattern of aggressive dealmaking by Lilly. Prior to announcing this latest purchase, the pharmaceutical company had already deployed over $10 billion in upfront payments across eight separate acquisitions throughout 2025, with aggregate potential payments approaching $25 billion when including milestone achievements.
This past June, Lilly finalized its purchase of Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, securing investigational therapies that modulate sleep-wake regulatory systems in the brain.
The company has strategically focused on acquiring late-stage assets commanding premium valuations as it reinforces its standing as the world’s most valuable healthcare enterprise by market capitalization.
Funding for this acquisition spree derives primarily from exceptional commercial performance of Lilly’s blockbuster obesity and diabetes medication portfolio. The company has systematically reinvested these substantial revenues into expanding its clinical development programs spanning neuroscience, immunology, and cancer therapeutics.
The AtaiBeckley acquisition is projected to reach completion during the third quarter of 2026.
The post Eli Lilly (LLY) Acquires Psychedelic Drug Developer AtaiBeckley in $2.8B Deal appeared first on Blockonomi.
